AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2016
May 3, 2016
31289_dirs_2016-05-03_ea160e9a-d668-43cf-a090-54fe6432ad9d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-05-02
Reporting Person: KOZARICH JOHN W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-05-02 | Common Stock | S | 800.0 | $121.45 | Disposed | 43911 | Direct |
| 2016-05-02 | Common Stock | S | 200.0 | $122.04 | Disposed | 43711 | Direct |
Footnotes
F1: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.98 to $121.90, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.98 to $122.10, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.